高乐氏(CLX)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 CLX 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q3 2026
Item	Category	Value	YoY
Net sales	revenue	1.67B	0.12%
Gross profit	profit	722.00M	-2.96%
Cost of products sold	cost	948.00M	2.60%
Earnings before income taxes	profit	256.00M	0.79%
Selling and administrative expenses	cost	229.00M	-14.23%
Advertising costs	cost	177.00M	-14.49%
Research and development costs	cost	27.00M	0.00%
Interest expense	cost	27.00M	17.39%
Other (income) expense, net	cost	6.00M	-82.35%
Net earnings	profit	191.00M	0.00%
Income tax expense	cost	65.00M	3.17%
Net earnings attributable to clorox	profit	187.00M	0.54%
Less: net earnings attributable to noncontrolling interests	cost	4.00M	-20.00%

Balance Sheet Q3 2026
Item	Category	Value
Cash and cash equivalents	assets	1.19B
Receivables, net	assets	671.00M
Inventories, net	assets	588.00M
Prepaid expenses and other current assets	assets	205.00M
Total current assets	assets	2.65B
Property, plant and equipment, net of accumulated depreciation and amortization of $3,044 and $2,911, respectively	assets	1.24B
Goodwill	assets	1.23B
Trademarks, net	assets	502.00M
Other assets	assets	415.00M
Operating lease right-of-use assets	assets	355.00M
Other intangible assets, net	assets	49.00M
Total assets	assets	6.44B
Total liabilities	liabilities	6.34B
Total clorox stockholders’ (deficit) equity	equity	67.00M
Total stockholders’ equity	liabilities	92.00M
Total current liabilities	liabilities	3.15B
Long-term debt	liabilities	2.49B
Other liabilities	liabilities	356.00M
Long-term operating lease liabilities	liabilities	323.00M
Deferred income taxes	liabilities	23.00M
Noncontrolling interests	liabilities	159.00M
Notes and loans payable	liabilities	1.59B
Accounts payable and accrued liabilities	liabilities	1.48B
Current operating lease liabilities	liabilities	85.00M

Operating Activities – 9M 2026
Item	Value
Net earnings	434.00M
Depreciation and amortization	169.00M
Increase (decrease) in receivables	158.00M
Deferred income tax expense (benefit)	135.00M
Stock-based compensation	49.00M
Operating lease right-of-use assets and liabilities, net	-5.00M
Increase (decrease) in accounts payable and accrued liabilities	-12.00M
Increase (decrease) in prepaid expense and other assets	-14.00M
Other noncash income (expense)	-18.00M
Increase (decrease) in inventories	-64.00M
Increase (decrease) in income taxes payable, net of income taxes receivable	-74.00M
Venture agreement termination payment	-476.00M

Investing Activities – 9M 2026
Item	Value
Payment for (proceeds from) other investing activity	1.00M
Payments to acquire property, plant, and equipment	-121.00M

Financing Activities – 9M 2026
Item	Value
Notes and loans payable, net	1.58B
Issuance of common stock for employee stock plans and other	-16.00M
Payments for repurchase of common stock	-256.00M
Payments of ordinary dividends, common stock	-452.00M

Cash Balance – 9M 2026
Item	Value
Cash and cash equivalents, beginning of period	170.00M
Cash and cash equivalents, end of period	1.19B